{
  "symbol": "ALVOW",
  "company_name": "Alvotech WT",
  "ir_website": "https://investors.alvotech.com/",
  "structured_data": [
    {
      "section_name": "Error Details",
      "links": [
        {
          "title": "This site can’t be reached",
          "url": "https://investors.alvotech.com",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/logo1.png) ](https://www.alvotech.com/)\n\n  * [](#)\n  * [Investors](/investors)\n  * [News & Events](/news-events/news-releases)\n    * [News Releases](/news-events/news-releases)\n    * [Events and Presentations](/news-events/events)\n    * [Earnings Calendar](/earnings-calendar)\n  * [Stock](/stock-information/stock-quote-chart)\n    * [Shareholders](/shareholders)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Governance](/corporate-governance/documents-charters)\n    * [Documents & Charters](/corporate-governance/documents-charters)\n    * [Management](https://www.alvotech.com/about-us/leadership)\n    * [Board of Directors](https://alvotech.com/board-of-directors)\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Annual General Meeting](/corporate-governance/annual-general-meeting-2024)\n  * [Filings & Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Public Company Filings](/publicfilings)\n    * [Financials](/financials)\n  * [IR Resources](/ir-resources/email-alerts)\n    * [Investor FAQs](/ir-resources/investor-faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\nINVESTOR RELATIONS\n\n# Broadening the accessibility of biologic medicines to patients around the world.\n\n[](#profile)\n\n## Overview\n\nAlvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.\n\n![Stock Chart](https://api.nasdaqomx.wallst.com/api/chart?display=line&symbol=ALVO&scale=linear&duration=1dy&frequency=15min&gridLine=h&bgColor=f4f6f8&lineColor=f99f1b&fillcolor=f99f1b|f99f1b&width=600&height=240&bdr=2&volume=0)\n\nMinimum 15 minutes delayed. Source: LSEG\n\n##  News Releases \n\n13 Nov '24\n\n[Alvotech Reports Financial Results for the First Nine Months of 2024](/news-releases/news-release-details/alvotech-reports-financial-results-first-nine-months-2024)\n\nTotal Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 million Product revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million,\n\n[HTML íslensk útgáfaNews Release link](https://www.alvotech.is/newsroom/alvotech-birtir-fjarhagsuppgjor-fyrstu-niu-manada-2024)\n\n07 Nov '24\n\n[Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024](/news-releases/news-release-details/alvotech-attending-citis-global-healthcare-conference-december-4)\n\nREYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare Conference in Miami, Florida on \n\n04 Nov '24\n\n[European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)](/news-releases/news-release-details/european-medicines-agency-confirms-acceptance-marketing-1)\n\nREYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic\n\n30 Oct '24\n\n[Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET](/news-releases/news-release-details/alvotech-report-financial-results-first-nine-months-2024)\n\nREYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after\n\n[HTML íslensk útgáfaNews Release link](https://www.alvotech.is/newsroom/alvotech-birting-a-uppgjori-q3-2024)\n\n[View All](/news-events/news-releases)\n\n##  Recent Events \n\n[Evercore's 7th Annual HealthCONx Conference, Coral Gables, FL](/events/event-details/evercores-7th-annual-healthconx-conference-miami)\n\nDecember 5, 2024 at 12:55 PM EST\n\n[Citi's 2024 Global Healthcare Conference](/events/event-details/citis-2024-global-healthcare-conference)\n\nDecember 4, 2024 \n\n[Jefferies London Healthcare Conference 2024](/events/event-details/jefferies-london-healthcare-conference-2024)\n\nNovember 19, 2024 from 9:00 AM to 9:25 AM GMT\n\n[View All](/news-events/events)\n\n##  Latest Financials \n\n[Fréttatilkynning Q3 2024](/static-files/32fdad7b-f778-46cf-bfbb-5a7385ad54d1 \"Fréttatilkynning Q3 2024.pdf\") 445.9 KB\n\n[Press Release Q3 2024](/static-files/cf25ce2d-32ab-40b3-97a2-8e5c0be99cda \"Press Release Q3 2024.pdf\") 398.3 KB\n\n[Presentation Q3 2024](/static-files/160d0e26-9f24-463e-9d39-b3aa20f8f329 \"Presentation Q3 2024.pdf\") 1.8 MB\n\n[Press Release Q2 2024](/static-files/fe3e70ea-0a03-4012-bf54-30ebc4744e1e \"Press Release Q2 2024.pdf\") 398.2 KB\n\n[View All](/financials)\n\n## Corporate Governance\n\n[View All Management](https://www.alvotech.com/about-us/leadership)\n\n[View All Directors](https://www.alvotech.com/board-of-directors)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-1.png) Stock Information Stock Information ](/stock-information/stock-quote-chart)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-2.png) Investor Contacts Investor Contacts ](/investor-contacts)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-3.png) Financial Calendar Financial Calendar ](/earnings-calendar)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-4.png) FAQ FAQ ](/ir-resources/investor-faqs)\n\nRequest Email Alerts\n\n[Back to top](#)\n"
        },
        {
          "title": "ERR_HTTP2_PROTOCOL_ERROR",
          "url": "https://investors.alvotech.com",
          "content": "[ Skip to main navigation ](#main-menu)\n\n[ ![logo](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/logo1.png) ](https://www.alvotech.com/)\n\n  * [](#)\n  * [Investors](/investors)\n  * [News & Events](/news-events/news-releases)\n    * [News Releases](/news-events/news-releases)\n    * [Events and Presentations](/news-events/events)\n    * [Earnings Calendar](/earnings-calendar)\n  * [Stock](/stock-information/stock-quote-chart)\n    * [Shareholders](/shareholders)\n    * [Stock Quote & Chart](/stock-information/stock-quote-chart)\n    * [Analyst Coverage](/stock-information/analyst-coverage)\n  * [Governance](/corporate-governance/documents-charters)\n    * [Documents & Charters](/corporate-governance/documents-charters)\n    * [Management](https://www.alvotech.com/about-us/leadership)\n    * [Board of Directors](https://alvotech.com/board-of-directors)\n    * [Committee Composition](/corporate-governance/committee-composition)\n    * [Annual General Meeting](/corporate-governance/annual-general-meeting-2024)\n  * [Filings & Financials](/financial-information/sec-filings)\n    * [SEC Filings](/financial-information/sec-filings)\n    * [Public Company Filings](/publicfilings)\n    * [Financials](/financials)\n  * [IR Resources](/ir-resources/email-alerts)\n    * [Investor FAQs](/ir-resources/investor-faqs)\n    * [Email Alerts](/ir-resources/email-alerts)\n    * [Contact IR](/ir-resources/contact-ir)\n\n\n\nINVESTOR RELATIONS\n\n# Broadening the accessibility of biologic medicines to patients around the world.\n\n[](#profile)\n\n## Overview\n\nAlvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.\n\n![Stock Chart](https://api.nasdaqomx.wallst.com/api/chart?display=line&symbol=ALVO&scale=linear&duration=1dy&frequency=15min&gridLine=h&bgColor=f4f6f8&lineColor=f99f1b&fillcolor=f99f1b|f99f1b&width=600&height=240&bdr=2&volume=0)\n\nMinimum 15 minutes delayed. Source: LSEG\n\n##  News Releases \n\n13 Nov '24\n\n[Alvotech Reports Financial Results for the First Nine Months of 2024](/news-releases/news-release-details/alvotech-reports-financial-results-first-nine-months-2024)\n\nTotal Revenues in the first nine months of 2024 increased by $300 million compared to same period in 2023, to $339 million, with Q3 revenues contributing $103 million Product revenues in the first nine months of 2024 increased over four-fold compared to the same period last year, to $128 million,\n\n[HTML íslensk útgáfaNews Release link](https://www.alvotech.is/newsroom/alvotech-birtir-fjarhagsuppgjor-fyrstu-niu-manada-2024)\n\n07 Nov '24\n\n[Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore’s HealthCONx Conference on December 5, 2024](/news-releases/news-release-details/alvotech-attending-citis-global-healthcare-conference-december-4)\n\nREYKJAVIK, Iceland, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in Citi’s 2024 Global Healthcare Conference in Miami, Florida on \n\n04 Nov '24\n\n[European Medicines Agency Confirms Acceptance of Marketing Authorization Application for AVT05, a Proposed Biosimilar to Simponi® (golimumab)](/news-releases/news-release-details/european-medicines-agency-confirms-acceptance-marketing-1)\n\nREYKJAVIK, Iceland and LONDON, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic\n\n30 Oct '24\n\n[Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET](/news-releases/news-release-details/alvotech-report-financial-results-first-nine-months-2024)\n\nREYKJAVIK, Iceland, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, will release financial results for first nine months of the year ended September 30, 2024, after\n\n[HTML íslensk útgáfaNews Release link](https://www.alvotech.is/newsroom/alvotech-birting-a-uppgjori-q3-2024)\n\n[View All](/news-events/news-releases)\n\n##  Recent Events \n\n[Evercore's 7th Annual HealthCONx Conference, Coral Gables, FL](/events/event-details/evercores-7th-annual-healthconx-conference-miami)\n\nDecember 5, 2024 at 12:55 PM EST\n\n[Citi's 2024 Global Healthcare Conference](/events/event-details/citis-2024-global-healthcare-conference)\n\nDecember 4, 2024 \n\n[Jefferies London Healthcare Conference 2024](/events/event-details/jefferies-london-healthcare-conference-2024)\n\nNovember 19, 2024 from 9:00 AM to 9:25 AM GMT\n\n[View All](/news-events/events)\n\n##  Latest Financials \n\n[Fréttatilkynning Q3 2024](/static-files/32fdad7b-f778-46cf-bfbb-5a7385ad54d1 \"Fréttatilkynning Q3 2024.pdf\") 445.9 KB\n\n[Press Release Q3 2024](/static-files/cf25ce2d-32ab-40b3-97a2-8e5c0be99cda \"Press Release Q3 2024.pdf\") 398.3 KB\n\n[Presentation Q3 2024](/static-files/160d0e26-9f24-463e-9d39-b3aa20f8f329 \"Presentation Q3 2024.pdf\") 1.8 MB\n\n[Press Release Q2 2024](/static-files/fe3e70ea-0a03-4012-bf54-30ebc4744e1e \"Press Release Q2 2024.pdf\") 398.2 KB\n\n[View All](/financials)\n\n## Corporate Governance\n\n[View All Management](https://www.alvotech.com/about-us/leadership)\n\n[View All Directors](https://www.alvotech.com/board-of-directors)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-1.png) Stock Information Stock Information ](/stock-information/stock-quote-chart)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-2.png) Investor Contacts Investor Contacts ](/investor-contacts)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-3.png) Financial Calendar Financial Calendar ](/earnings-calendar)\n\n[ ![](/sites/g/files/knoqqb73151/themes/site/nir_pid7639/dist/images/link/link-4.png) FAQ FAQ ](/ir-resources/investor-faqs)\n\nRequest Email Alerts\n\n[Back to top](#)\n"
        }
      ]
    }
  ]
}